James R Johnson1,2, Stephen Porter1,2, Paul Thuras1,2, Mariana Castanheira3. 1. Minneapolis Veterans Affairs Healthcare System. 2. Departments of Medicine and Psychiatry, University of Minnesota, Minneapolis; and. 3. JMI Laboratories, North Liberty, Iowa.
Abstract
BACKGROUND: Extraintestinal Escherichia coli infections are increasingly challenging due to emerging antimicrobial resistance, including resistance to extended-spectrum beta-lactams and fluoroquinolones. Sequence type 131 (ST131) is a leading contributor. METHODS: Three hundred sixty E. coli clinical isolates from across the United States (2011-2012), selected randomly from the SENTRY collection within 3 resistance categories (extended-spectrum cephalosporin [ECS]-reduced susceptibility [RS]; fluoroquinolone-resistant, ESC-susceptible; and fluoroquinolone-susceptible, ESC-susceptible) were typed for phylogroup, sequence type complex (STc), subsets thereof, virulence genotype, O type, and beta-lactamase genes. Molecular results were compared with susceptibility profile, specimen type, age, and sex. RESULTS: Phylogroup B2 accounted for most isolates, especially fluoroquinolone-resistant isolates (83%). Group B2-derived ST131 and its H30 subclone (divided between H30Rx and H30R1) predominated, especially among ESC-RS and fluoroquinolone-resistant isolates. In contrast, among fluoroquinolone-susceptible isolates, group B2-derived STc73 and STc95 predominated. Within each resistance category, ST131 isolates exhibited more extensive resistance and/or virulence profiles than non-ST131 isolates. ST131-H30 was distributed broadly by geographical region, age, and specimen type and exhibited distinctive beta-lactamase genes. Back-calculations indicated that within the source population ST131 accounted for 26.4% of isolates overall (vs 17% in 2007), including 19.8% ST131-H30, 13.2% ST131-H30R1, and 6.6% each ST131-H30Rx and non-H30 ST131. CONCLUSIONS: ST131-H30, with its ESC resistance-associated H30Rx subset, caused most antimicrobial-resistant E. coli infections across the United States in 2011-2012 and, since 2007, increased in relative prevalence by >50%. Focused attention to this strain could help combat the current E. coli resistance epidemic. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Extraintestinal Escherichia coli infections are increasingly challenging due to emerging antimicrobial resistance, including resistance to extended-spectrum beta-lactams and fluoroquinolones. Sequence type 131 (ST131) is a leading contributor. METHODS: Three hundred sixty E. coli clinical isolates from across the United States (2011-2012), selected randomly from the SENTRY collection within 3 resistance categories (extended-spectrum cephalosporin [ECS]-reduced susceptibility [RS]; fluoroquinolone-resistant, ESC-susceptible; and fluoroquinolone-susceptible, ESC-susceptible) were typed for phylogroup, sequence type complex (STc), subsets thereof, virulence genotype, O type, and beta-lactamase genes. Molecular results were compared with susceptibility profile, specimen type, age, and sex. RESULTS: Phylogroup B2 accounted for most isolates, especially fluoroquinolone-resistant isolates (83%). Group B2-derived ST131 and its H30 subclone (divided between H30Rx and H30R1) predominated, especially among ESC-RS and fluoroquinolone-resistant isolates. In contrast, among fluoroquinolone-susceptible isolates, group B2-derived STc73 and STc95 predominated. Within each resistance category, ST131 isolates exhibited more extensive resistance and/or virulence profiles than non-ST131 isolates. ST131-H30 was distributed broadly by geographical region, age, and specimen type and exhibited distinctive beta-lactamase genes. Back-calculations indicated that within the source population ST131 accounted for 26.4% of isolates overall (vs 17% in 2007), including 19.8% ST131-H30, 13.2% ST131-H30R1, and 6.6% each ST131-H30Rx and non-H30 ST131. CONCLUSIONS:ST131-H30, with its ESC resistance-associated H30Rx subset, caused most antimicrobial-resistant E. coli infections across the United States in 2011-2012 and, since 2007, increased in relative prevalence by >50%. Focused attention to this strain could help combat the current E. coli resistance epidemic. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper Journal: Clin Infect Dis Date: 2011-03-01 Impact factor: 9.079
Authors: James R Johnson; Stephen Porter; Brian Johnston; Michael A Kuskowski; Rachel R Spurbeck; Harry L T Mobley; Deborah A Williamson Journal: Open Forum Infect Dis Date: 2015-06-06 Impact factor: 3.835
Authors: James R Johnson; Megan Menard; Brian Johnston; Michael A Kuskowski; Kim Nichol; George G Zhanel Journal: Antimicrob Agents Chemother Date: 2009-04-27 Impact factor: 5.191
Authors: James R Johnson; Gregg Davis; Connie Clabots; Brian D Johnston; Stephen Porter; Chitrita DebRoy; William Pomputius; Peter T Ender; Michael Cooperstock; Billie Savvas Slater; Ritu Banerjee; Sybille Miller; Dagmara Kisiela; Evgeni V Sokurenko; Maliha Aziz; Lance B Price Journal: Open Forum Infect Dis Date: 2016-06-16 Impact factor: 3.835
Authors: Veronika Tchesnokova; Hovhannes Avagyan; Elena Rechkina; Diana Chan; Mariya Muradova; Helen Ghirmai Haile; Matthew Radey; Scott Weissman; Kim Riddell; Delia Scholes; James R Johnson; Evgeni V Sokurenko Journal: PLoS One Date: 2017-03-28 Impact factor: 3.240
Authors: Nicola K Petty; Nouri L Ben Zakour; Mitchell Stanton-Cook; Elizabeth Skippington; Makrina Totsika; Brian M Forde; Minh-Duy Phan; Danilo Gomes Moriel; Kate M Peters; Mark Davies; Benjamin A Rogers; Gordon Dougan; Jesús Rodriguez-Baño; Alvaro Pascual; Johann D D Pitout; Mathew Upton; David L Paterson; Timothy R Walsh; Mark A Schembri; Scott A Beatson Journal: Proc Natl Acad Sci U S A Date: 2014-03-31 Impact factor: 11.205
Authors: Brian D Johnston; Paul Thuras; Stephen B Porter; Melissa Anacker; Brittany VonBank; Paula Snippes Vagnone; Medora Witwer; Mariana Castanheira; James R Johnson Journal: Antimicrob Agents Chemother Date: 2020-09-21 Impact factor: 5.191
Authors: Ivana Jamborova; Brian D Johnston; Ivo Papousek; Katerina Kachlikova; Lenka Micenkova; Connie Clabots; Anna Skalova; Katerina Chudejova; Monika Dolejska; Ivan Literak; James R Johnson Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191
Authors: Muhanad Mohamed; Connie Clabots; Stephen B Porter; Tricia Bender; Paul Thuras; James R Johnson Journal: J Infect Dis Date: 2020-04-27 Impact factor: 5.226
Authors: James R Johnson; Brian D Johnston; Stephen B Porter; Connie Clabots; Tricia L Bender; Paul Thuras; Darren J Trott; Rowland Cobbold; Joanne Mollinger; Patricia Ferrieri; Sarah Drawz; Ritu Banerjee Journal: J Clin Microbiol Date: 2019-04-26 Impact factor: 5.948
Authors: Brian D Johnston; Paul Thuras; Stephen B Porter; Melissa Anacker; Brittany VonBank; Paula Snippes Vagnone; Medora Witwer; Mariana Castanheira; James R Johnson Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: Shehara M Mendis; Shawn Vasoo; Brian D Johnston; Stephen B Porter; Scott A Cunningham; Sanjay R Menon; Christine B Teng; Partha P De; Robin Patel; James R Johnson; Ritu Banerjee Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191
Authors: Valentine Murigneux; Leah W Roberts; Brian M Forde; Minh-Duy Phan; Nguyen Thi Khanh Nhu; Adam D Irwin; Patrick N A Harris; David L Paterson; Mark A Schembri; David M Whiley; Scott A Beatson Journal: BMC Genomics Date: 2021-06-25 Impact factor: 3.969